To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy

S. M. Yin; D. L. Li

doi:10.1016/j.stem.2024.10.009

To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy

S. M. Yin
, D. L. Li^*

^*Corresponding author for this work

School of Life Sciences

East China Normal University

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

Epitope editing is a promising strategy for protecting hematopoietic cells from eradication by immunotherapies. Recently, in Cell Stem Cell, Ji et al. applied both base editing (BE) and prime editing (PE) to alter the epitope of CD123 in hematopoietic stem cells for CAR-T therapy against acute myeloid leukemia.¹

Original language	English
Pages (from-to)	1557-1559
Number of pages	3
Journal	Cell Stem Cell
Volume	31
Issue number	11
DOIs	https://doi.org/10.1016/j.stem.2024.10.009
State	Published - 7 Nov 2024

Access to Document

10.1016/j.stem.2024.10.009

Cite this

@article{e951249bf3574807971547e560e8cb71,

title = "To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy",

abstract = "Epitope editing is a promising strategy for protecting hematopoietic cells from eradication by immunotherapies. Recently, in Cell Stem Cell, Ji et al. applied both base editing (BE) and prime editing (PE) to alter the epitope of CD123 in hematopoietic stem cells for CAR-T therapy against acute myeloid leukemia.1",

author = "Yin, \{S. M.\} and Li, \{D. L.\}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Inc.",

year = "2024",

month = nov,

day = "7",

doi = "10.1016/j.stem.2024.10.009",

language = "英语",

volume = "31",

pages = "1557--1559",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "11",

}

TY - JOUR

T1 - To BE or to PE

T2 - Prime editors provide more choices for epitope-editing-based immunotherapy

AU - Yin, S. M.

AU - Li, D. L.

PY - 2024/11/7

Y1 - 2024/11/7

N2 - Epitope editing is a promising strategy for protecting hematopoietic cells from eradication by immunotherapies. Recently, in Cell Stem Cell, Ji et al. applied both base editing (BE) and prime editing (PE) to alter the epitope of CD123 in hematopoietic stem cells for CAR-T therapy against acute myeloid leukemia.1

AB - Epitope editing is a promising strategy for protecting hematopoietic cells from eradication by immunotherapies. Recently, in Cell Stem Cell, Ji et al. applied both base editing (BE) and prime editing (PE) to alter the epitope of CD123 in hematopoietic stem cells for CAR-T therapy against acute myeloid leukemia.1

UR - https://www.scopus.com/pages/publications/85207806050

U2 - 10.1016/j.stem.2024.10.009

DO - 10.1016/j.stem.2024.10.009

M3 - 评论/辩论

C2 - 39515298

AN - SCOPUS:85207806050

SN - 1934-5909

VL - 31

SP - 1557

EP - 1559

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 11

ER -

To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this